Form 4: Genelux Corp VP, Clinical Trial Operations, Yu Yong, Reports Sale of Common Stock
SEC Form 4 Filing
Yu Yong, VP of Clinical Trial Operations at Genelux Corp, reports the sale of 5,579 shares of common stock at $2.92 per share to cover estimated taxes related to vesting restricted stock units.
Summary
- On May 12, 2025, Yu Yong, VP, Clinical Trial Operations at Genelux Corp, sold 5,579 shares of common stock.
- The sale price was $2.92 per share.
- The transaction was executed to cover estimated taxes related to the vesting of restricted stock units.
- Following the transaction, Yu Yong directly owns 47,640 shares of Genelux Corp common stock.
Sentiment
Score: 5
Explanation: The document is a standard regulatory filing related to an insider stock sale for tax purposes, which is neutral in sentiment.
Industry Context
This Form 4 filing is a routine disclosure required by the SEC when a company insider, like a VP, transacts in their company's stock. It provides transparency to the market regarding insider activity.
Stakeholder Impact
- The sale of shares by a company insider could be perceived negatively by some shareholders, although this sale is explicitly stated to cover tax obligations related to vested restricted stock units.
Key Dates
| Date | Description |
|---|---|
| 05/12/2025 | Date of transaction: Sale of common stock. |
| 05/13/2025 | Date of signature by Attorney-in-Fact. |
Keywords
Form 4, Beneficial Ownership, GENELUX Corp, GNLX, Yu Yong, Clinical Trial Operations, Stock Sale, Restricted Stock Units, Tax Obligations
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.